NOD1 Agonist Protects Against Lipopolysaccharide and D-Galactosamine-Induced Fatal Hepatitis Through the Upregulation of A20 Expression in Hepatocytes.
NOD1 Agonist Protects Against Lipopolysaccharide and D-Galactosamine-Induced Fatal Hepatitis Through the Upregulation of A20 Expression in Hepatocytes.
复制标题
NOD1 激动剂通过上调肝细胞中 A20 的表达来预防脂多糖和 D-半乳糖胺诱导的致命性肝炎。
DOI:
10.3389/fimmu.2021.603192
复制
发表时间:
2021
影响因子:
7.3
通讯作者:
Yin W
中科院分区:
文献类型:
--
作者:
Jia F;Deng F;Xu P;Li S;Wang X;Hu P;Ren H;Tong S;Yin W
Increasing evidence suggests that NODs are involved in liver diseases; however, the underlying mechanisms remain obscure. In the present study, we analyzed the effect of NOD1 agonist pretreatment on acute liver failure induced by lipopolysaccharide (LPS) in D-galactosamine (D-GalN)-sensitized mice. We found that pretreatment with the NOD1 agonist markedly reduced LPS/D-GalN-induced mortality, elevation of serum ALT levels, and hepatocyte apoptosis. The protective effect of NOD1 agonist was independent of tumor necrosis factor (TNF)-α inhibition. NOD1 agonist pretreatment also attenuated TNF-α/D-GalN-induced apoptotic liver damage. The anti-apoptotic protein A20 expression was more pronounced in NOD1 agonist pretreated mice than in controls, and knockdown of A20 abrogated the protective effect of NOD1 agonist on LPS/D-GalN-induced liver injury and hepatocyte apoptosis. Further experiments showed that NOD1 agonist-induced A20 upregulation required the presence of kupffer cells and TNF-α. Taken together, our data strongly indicate that NOD1 is involved in the regulation of liver injury and could be a potential therapeutic target for liver diseases.
登录
查看更多内容
影响因子:
4.4
作者:
Huang, Shunmei;Zou, Shi;Wu, Jun
通讯作者:
Wu, Jun
影响因子:
4.8
作者:
Girardin, SE;Travassos, LH;Mengin-Lecreulx, D
通讯作者:
Mengin-Lecreulx, D
影响因子:
7.2
作者:
Kuhla, Angela;Eipel, Christian;Vollmar, Brigitte
通讯作者:
Vollmar, Brigitte
影响因子:
3.4
作者:
Vakili, Sanaz;Ebrahimi, Shadi Sadat Seyyed;Meshkani, Reza
通讯作者:
Meshkani, Reza
影响因子:
--
作者:
Seglen, P O
通讯作者:
Seglen, P O